genprowebdirectory
GEN Edge
Featured News
Multimedia
Subscribe
Login
Contributors
News
Insights
Trends for 2020
Trends for 2021
Trends for 2023
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
A-Lists
Magazine
Current Issue
Past Issues
Supplements
Subscribe
Multimedia
Summits
Webinars
Learning Labs
GEN Live
Podcasts
Resources
eBooks/Perspectives
Tutorials
Biotech Briefs
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Best of the Web
Best Apps
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Get GEN Edge
Search
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
your email
A password will be e-mailed to you.
GEN – Genetic Engineering and Biotechnology News
GEN Edge
Featured News
Multimedia
Subscribe
Login
Contributors
News
Drug Discovery
First-In-Human Trial of Marburg Vaccine Shows Promising Results
Infectious Disease Diagnostics
Exploring Ways to Block Malaria Transmission
Infectious Diseases
Collective Measles Virus Mutations Linked to Fatal Encephalitis
Genome Editing
Catalent Opens New Commercial-Scale Plasmid DNA Manufacturing Facility
Infectious Diseases
Repeated Malaria Expands Innate Immune Cell-Type in Ugandan Children
Insights
All
Trends for 2020
Trends for 2021
Trends for 2023
Blood Disorders
Sustained Graft-Versus-Host Disease Depends on Tissue-Resident Seeds
Artificial Intelligence
Chiral Spectroscopy Lessens the Chiral Resolution Stumbling Block
Genome Editing
Advanced Therapies Could Be Sleepwalking into a Manufacturing Cost Crisis
Genome Editing
Cell and Gene Therapy Scale-Up Challenges
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
A-Lists
Drug Discovery
Seven Biopharma Trends to Watch in 2023
A-Lists
Top 50 NIH-Funded Institutions of 2022
A-Lists
Top 10 U.S. Biopharma Clusters
A-Lists
Top 10 Spatial Biology Companies
A-Lists
Top 25 Biotech Companies of 2022
Magazine
Current Issue
Past Issues
Supplements
Subscribe
Multimedia
Summits
Webinars
Learning Labs
GEN Live
Podcasts
Resources
eBooks/Perspectives
Tutorials
Biotech Briefs
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Best of the Web
Best Apps
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Get GEN Edge
Home
Topics
Genome Editing
Page 3
Genome Editing
CRISPR-Cas9
Gene Therapy
Synthetic Biology
Featured posts
Latest
Featured posts
Most popular
7 days popular
By review score
Random
On Demand Webinars
Improving Plasmid and Viral Vectors in Cell and Gene Therapy
Genome Editing
Gene Therapy Molecular Switch May Control Dosing
Genome Editing
Forces Unite to Move Molecular Dx Out of the Gates
Genome Editing
Genome Editing Heads to Primetime
Genome Editing
Novel Gene Therapy for Duchenne Muscular Dystrophy Shows Promise
CRISPR-Cas9
CRISPR-Cas9 Inhibitors Found in Metagenomics Study
Companies
J&J’s Janssen to Develop MeiraGTx’s Retinal Disease Gene Therapies
Companies
In $1.9B Alliance, Neurocrine to Develop Voyager Gene Therapies for Parkinson’s,...
Genome Editing
A Conversation with Emmanuelle Charpentier
Genome Editing
Licensing Deal Moves Merck KGaA, Vertex Further into Gene Editing-Based Drug...
Genome Editing
Gene Drive Feasible in Mammals, Not Just Insects
Gene Therapy
Nerve Regeneration Pumped Up by Muscle Protein
Genome Editing
Diversifying the CRISPR Toolbox
Genome Editing
He Jiankui Fired in Wake of CRISPR Babies Investigation
Genome Editing
Orchard Therapeutics Plans 3 Approval Submissions, In-House Manufacturing by 2021
1
2
3
4
...
6
Page 3 of 6
Scroll Up
Login
Subscribe
![Firm had previously rejected Astellas’ unsolicited bid of roughly $3.5 billion. [© Yuri Arcurs - Fotolia.com]](https://www.genengnews.com/wp-content/uploads/2018/08/May17_2010_495175_HandshakeBirdsEyeView_AstellasBuysOSI7721122207-2-265x198.jpg "Forces Unite to Move Molecular Dx Out of the Gates")
![Spark Therapeutics saw its share price tumble about 30% in early-morning trading after it reported mixed preliminary data this morning from a Phase I/II trial of its hemophilia A gene therapy candidate SPK-8001. [Source: wildpixel/Getty Images]](https://www.genengnews.com/wp-content/uploads/2018/08/Dec7_2017_Getty_487489316_GeneTherapy_60019871441892139879144-265x198.jpg "Novel Gene Therapy for Duchenne Muscular Dystrophy Shows Promise")
